Lung cancer Board decisions

The Board remands the matter of entitlement to service connection for lung cancer due to a lack of substantial compliance with prior remands.

The Board granted service connection for adenoid cystic carcinoma of the right submandibular gland and lung cancer, secondary to adenoid cystic carcinoma of the right submandibular gland, based on herbicide exposure during active duty in Vietnam.

The Board denied service connection for colon cancer, lung cancer, benign prostatic hypertrophy (BPH), and chronic kidney disease (CKD) as the evidence did not support a finding that these conditions were related to the Veteran's active duty or exposure to herbicide agents.

The Board remanded the case for the AOJ to gather missing medical and transportation records necessary to determine whether the Veteran's special mode transportation on December 26-27, 2024 qualifies for payment or reimbursement under 38 U.S.C. §§ 111 and 1728. The decision was necessary because critical records relating to the ambulance transportation, hospital treatment, and VA authorization/reimbursement status were absent from the claims file.

The Board granted service connection for colorectal cancer, prostate cancer, and lung cancer based on new evidence and the Veteran's exposure to contaminated Camp Lejeune water.

The Board granted service connection for the cause of death, finding that toxic exposure during service contributed substantially or materially to the Veteran's cause of death.

The Board denied the claim for service connection for lung cancer, as there was no evidence to establish that the Veteran's lung cancer was incurred in or caused by his military service, including any exposure to ionizing radiation.

The Board remands the Veteran's claims for service connection for small bowel cancer, lung cancer, prostate cancer, and skin cancer to correct a pre-decisional duty-to-assist error related to VA's statutory duties under the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 (PACT Act).

The Board granted an earlier effective date of May 1, 2015, for the award of service connection for the Veteran's cause of death due to lung cancer.

The Board denied service connection for the cause of the Veteran's death, finding that there was not persuasive evidence linking his lung cancer to his military service.

The Board granted service connection for lung cancer, but remanded the claims for COPD, emphysema, bilateral feet condition to include nails, acquired psychiatric disability, and TDIU.

The Board remands the claims for service connection for COPD, lung cancer, and sinusitis to obtain additional medical opinions.

The Board granted service connection for diabetes mellitus due to Agent Orange exposure, right and left lower extremity peripheral neuropathy as secondary to type II diabetes mellitus, and lung cancer.

The Board granted service connection for the cause of death, finding that the Veteran's lung cancer was related to herbicide exposure during his service on the USS Enterprise.

The Board remands the claim for an adequate opinion regarding the Veteran's lung cancer, as the previous VA examination did not address in-service asbestos exposure.

The Board denied the Veteran's appeal for an earlier effective date for service connection of lung cancer disability, with an initial rating of 100 percent.

The Board granted service connection for the cause of death, lung cancer, and small cell carcinoma behind the eyes due to toxic exposure during service at Camp Lejeune.

The Board remands the claims for a more adequate medical opinion regarding the etiology of the Veteran's cause of death, specifically addressing exposure to Agent Orange and contaminated drinking water at Camp Lejeune.

The Board remands the service connection claims for various cancers and eye conditions due to an alleged failure to properly investigate toxic exposures during service, including at Fort Wainwright.

The Veteran withdrew his appeal regarding the reduction of the evaluation for Lung Cancer Stage III, from 100 percent disabling to 30 percent disabling effective September 1, 2025.